Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Hanna et al. (Wed,) studied this question.

www.synapsesocial.com/papers/68e6dc18b6db643587657f34 — DOI: https://doi.org/10.1038/s41416-024-02685-9

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer· 2018 · 4,320 citations
2. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs· 2018 · 93 citations
3. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort· 2018 · 278 citations
4. Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy· 2008 · 157 citations
5. Changing Treatment Paradigms in Metastatic Breast Cancer· 2015 · 104 citations